UBS Group Has Lowered Expectations for Boston Scientific (NYSE:BSX) Stock Price

Boston Scientific (NYSE:BSX) had its price target reduced by stock analysts at UBS Group from $120.00 to $105.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. UBS Group’s price target suggests a potential upside of 47.29% from the company’s current price.

A number of other analysts have also recently commented on BSX. Weiss Ratings cut shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Argus upgraded Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Morgan Stanley decreased their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Stifel Nicolaus lowered their price target on Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Finally, TD Cowen dropped their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $107.18.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $71.29 on Tuesday. The firm’s 50 day simple moving average is $80.88 and its 200 day simple moving average is $92.56. Boston Scientific has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The company has a market capitalization of $105.78 billion, a price-to-earnings ratio of 36.75, a P/E/G ratio of 1.00 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts forecast that Boston Scientific will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BSX. Rockefeller Capital Management L.P. raised its position in Boston Scientific by 70.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 595,938 shares of the medical equipment provider’s stock valued at $56,823,000 after buying an additional 247,097 shares during the last quarter. Bank of New Hampshire boosted its position in Boston Scientific by 2.4% during the 4th quarter. Bank of New Hampshire now owns 22,159 shares of the medical equipment provider’s stock worth $2,113,000 after acquiring an additional 523 shares during the last quarter. World Investment Advisors grew its stake in shares of Boston Scientific by 2.2% during the 4th quarter. World Investment Advisors now owns 19,365 shares of the medical equipment provider’s stock worth $1,846,000 after acquiring an additional 411 shares in the last quarter. Farmers National Bank acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $204,000. Finally, Corient Private Wealth LLC raised its holdings in shares of Boston Scientific by 2.6% in the fourth quarter. Corient Private Wealth LLC now owns 224,554 shares of the medical equipment provider’s stock valued at $21,437,000 after purchasing an additional 5,756 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific’s European urology portfolio expanded with sacral neuromodulation following the Axonics deal, supporting recurring revenue growth in a defensive medtech category. Sacral neuromodulation broadening Boston Scientific’s European urology portfolio
• Positive Sentiment: Analysts continue to rate BSX as a buy: UBS and Truist trimmed price targets (UBS $120→$105; Truist $95→$92) but retained buy ratings, signaling ongoing analyst conviction even after downward target adjustments. Benzinga analyst notes
• Neutral Sentiment: Coverage pieces position Boston Scientific as a defensive healthcare hedge versus cyclically sensitive sectors, which can attract flows in volatile markets but is not an immediate catalyst. The Highest-Rated Healthcare Stock to Buy Now
• Neutral Sentiment: Industry hires and competitor moves (e.g., Field Medical naming a new CEO with Medtronic experience) are notable for competitive dynamics but are not direct, immediate earnings catalysts for BSX. Field Medical appoints Mark Turco as CEO
• Negative Sentiment: Multiple law firms and plaintiff notices warn Boston Scientific investors of a securities‑class‑action covering purchases from July 23, 2025 to Feb 3, 2026, with a May 4, 2026 lead‑plaintiff deadline — this surge of legal filings/notices increases potential litigation risk and uncertainty. Rosen Law Firm investor alert
• Negative Sentiment: Specific allegations (highlighted by firms such as Levi & Korsinsky) claim executives misrepresented U.S. electrophysiology procedure volumes — if proven, these allegations could lead to meaningful financial and reputational impact. Levi & Korsinsky investor alert

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.